Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

10x Genomics (TXG) Cash from Investing Activities (2018 - 2025)

Historic Cash from Investing Activities for 10x Genomics (TXG) over the last 8 years, with Q4 2025 value amounting to -$1.8 million.

  • 10x Genomics' Cash from Investing Activities rose 9650.14% to -$1.8 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$13.4 million, marking a year-over-year increase of 5881.83%. This contributed to the annual value of -$13.4 million for FY2025, which is 5881.83% up from last year.
  • 10x Genomics' Cash from Investing Activities amounted to -$1.8 million in Q4 2025, which was up 9650.14% from -$8.8 million recorded in Q3 2025.
  • 10x Genomics' 5-year Cash from Investing Activities high stood at $120.0 million for Q1 2023, and its period low was -$257.6 million during Q1 2022.
  • In the last 5 years, 10x Genomics' Cash from Investing Activities had a median value of -$6.6 million in 2023 and averaged -$18.5 million.
  • Per our database at Business Quant, 10x Genomics' Cash from Investing Activities plummeted by 144404.58% in 2021 and then skyrocketed by 36774.99% in 2024.
  • 10x Genomics' Cash from Investing Activities (Quarter) stood at -$27.6 million in 2021, then decreased by 20.11% to -$33.2 million in 2022, then skyrocketed by 139.49% to $13.1 million in 2023, then tumbled by 493.89% to -$51.6 million in 2024, then surged by 96.5% to -$1.8 million in 2025.
  • Its Cash from Investing Activities was -$1.8 million in Q4 2025, compared to -$8.8 million in Q3 2025 and -$939000.0 in Q2 2025.